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Human b-myosin heavy chain mRNA prevalence is inversely related to
the degree of methylation of regulatory elements
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Abstract
Objective: Methylation of cytosine in CG dinucleotides within regulatory elements is believed to silence gene expression. These
. dinucleotides occur in certain important regulatory elements in the promoter region of the human b-myosin heavy chain b-MHC gene.
 We therefore investigated whether methylation of these elements correlates with b-MHC gene transcription in human ‘expressing’ right
. .  . atrial and ‘non-expressing’ peripheral blood leucocytes cells. Methods: We employed 2 techniques to assess promoter methylation: i
analysis of the susceptibility to digestion of a particular CCGG restriction site in the promoter region when genomic DNA is cleaved with
.  .  . the restriction endonucleases MspI methylation-insensitive and HpaII methylation-sensitive , and ii the bisulphite-PCR method to
examine in detail the methylation patterns of 3 important regulatory elements that contain CG dinucleotides. b-MHC mRNA expression
in right atrium and leucocytes was assessed using reverse-transcription-PCR with specific primers that do not detect a-MHC cDNA.
Results: The digestion pattern observed with MspI or HpaII indicated that the CCGG site was almost completely methylated in
leucocytes, but relatively unmethylated in atrial myocardium from the same patients. When methylation was examined with the
bisulphite-PCR method we found a reciprocal relationship between the level of b-MHC mRNA expression in leucocytes and atrial
myocardium and the degree of methylation of CG dinucleotides in the 5
X regulatory elements of the gene. Conclusions: Tissue-specific
methylation of the human b-MHC gene promoter may play a role in determining the pattern of expression of this gene. Furthermore,
alteration of the level of methylation may underlie the changes in transcription of this gene that occur, for example, when atrial or
ventricular myocardium hypertrophies. q1998 Elsevier Science B.V. All rights reserved.
Keywords: Human; Myosin; DNA methylation; Hypertrophic cardiomyopathy; Bisulphite; Gene expression; Heart; RT-PCR
1. Introduction
Myosin molecules in the thick filament of the sarcom-
ere are encoded by 2 closely related genes, the a- and
. b-myosin heavy chain genes a-MHC and b-MHC which
are expressed in a tissue specific manner. In man, slow
twitch skeletal muscle is the only tissue, apart from the
heart, that expresses b-MHC. In the normal adult human
ventricle b-MHC predominates, whilst in atrial tissue a-
MHC is more prevalent, although there is still substantial
wx expression of b-MHC 1 . In rodents, normal left ventricu-
lar myocardium expresses mainly a-MHC. In both ventri-
cles and atria, the MHC genes are differentially expressed
) . . Corresponding author. Tel.: q44 181 383 3219; Fax: q44 181
383 2066; E-mail: d.nunez@rpms.ac.uk
in response to stimuli such as pressure overload and
thyroid hormone.
The transcriptional control mechanisms responsible for
these differences in b-MHC expression are not well under-
wx stood 2–4 , although several regulatory sequences at the
5
X-end of the gene have been identified, including a thyroid
response element which represses the b-MHC gene, but
activates the a-MHC gene, and strong positive and nega-
tive elements between positions y340 and y200 up-
wx stream from the transcription start site 3 . Some of these
. regulatory elements contain CG dinucleotides Table 1
that are susceptible to methylation at the 5
X position of the
cytosine base, a process which can silence the expression
Time for primary review 29 days.
0008-6363r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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Table 1
wx Adapted from 3 .
wx of a gene 5,6 . We therefore reasoned that differential
methylation of one or more CG-containing regulatory ele-
ments in the b-MHC gene may affect its transcription and
could underlie the differences in expression of this gene
between tissues.
2. Methods
2.1. Preparation of DNA from human peripheral blood
leucocytes and cardiac muscle
Right atrial tissue and a 10 ml peripheral venous blood
sample were obtained at the time of cardiac surgery from 3
patients undergoing coronary artery bypass surgery. Ge-
nomic DNA was then extracted using the Nucleon II
. genomic DNA extraction kit Scotlab according to the
manufacturer’s protocol. At the end of the protocol the
DNA was precipitated with ethanol and pelleted by cen-
trifugation, before being resuspended in 1 ml nuclease-free
sterile water.
Genomic DNA was extracted from 1 g blocks of human
right atrial tissue using a similar protocol designed for
 solid tissues as recommended by the supplier Nucleon II
. kit, Scotlab .
2.2. Preparation of RNA from human peripheral blood
leucocytes and cardiac muscle
Human peripheral blood leucocytes were concentrated
wx using a dextran density gradient 7 . The white blood cells
were pelleted by centrifugation at 1200 rpm for 6 min.
The white cell pellet and right atrial tissue were stored
at y808C until RNA extraction was performed using the
Hybaid Ribolyser kit according to the manufacturer’s pro-
. tocol Life Sciences . At the end of the procedure, the
RNA was precipitated with isopropanol. The RNA pellet
was then washed with saltrethanol solution, air-dried, and
resuspended in 100 ml nuclease-free water.
( 2.3. ReÍerse transcription-polymerase chain reaction RT-
) PCR
The reverse transcription reaction was performed as
wx previously described 8 , using 150 pmol of 12 mer ran-
domer, 4 ml RNA and 9 U MMLV reverse transcriptase
. Pharmacia . The reaction was incubated at 378C for 2 h,
and then made up to 100 ml with nuclease-free distilled
water.
For amplification of b-MHC cDNA, 2 primers were
designed from the human b-MHC gene sequence targeted
wx to the adjacent ends of exons 5–6 and 11–12 9 forward
primer: 5
X-CAGTACATGCTGACAGACAGA; reverse
X . primer: 5-GCACATCAAAAGCGTTATCAG . The PCR
reaction mixture contained 1.5 mmolrl MgCl , 200 2
mmolrl deoxynucleotides, 1 unit of Prozyme DNA poly-
. merase Bioline , 2.5 ml of cDNA and 1 mm each primer.
 PCR amplification was performed for 35 cycles denatura-
tion: 938C 30 s; annealing 588C 30 s; extension 728C1
. min; final extension 728C 10 min . The PCR products were
resolved by electrophoresis through a 1.8% agarose gel
and visualised using ethidium bromide staining. In addition
to flanking intronic sequences, there were 3 mismatches of
the primers at the 3
X end when compared with the a-MHC
cDNA sequence, which, as a consequence should not be
amplified. After electrophoretic separation, representative
samples of the amplified atrial DNA bands were purified
 from the agarose gel using GeneClean glass milk Bio
. 101 . The source of the PCR products was determined by
dideoxy sequencing with the Amplitaq FS Cycle Sequenc-
. ing kit as recommended by the supplier Perkin Elmer .
2.4. Analysis of methylation patterns using isoschizomeric
restriction enzymes and PCR

X Primers forward: 5-TTCTAGTGACAACAGCCC; re-
X . verse: 5-CATACCCTTTCTCACATTC were designed to
flank a CCGG MspIrHpaII restriction site within the
 promoter region of the human b-MHC gene bases 2462 to
wx . 2465 of the gene sequence 9 . Cleavage with HpaII will
only occur if the cytosine within the CG dinucleotide is
unmethylated, whilst MspI cleavage is not dependent on
the methylation status. Therefore, using this pair of restric-
tion enzymes it is possible to determine whether the
cytosine base is methylated or not.
. Genomic DNA 2 mg was pre-incubated with 1 mlo f
. . MspI 20 U or HpaII 10 U and 1 mlo f1 0 = restriction
. enzyme buffer New England Biolabs at 378C for 2 h. The
partially-digested DNA was denatured at 958C for 5 min
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before adding a further 1 ml of restriction enzyme and
leaving the reagents to incubate overnight at 378C. The
restriction enzyme was then inactivated by incubating the
reaction mix at 958C for 30 min. In the positive ‘no-en-
zyme’ control the restriction enzymes were omitted, and 2
ml of the buffer were used instead. 2.5 ml of the digested
or ‘buffer-only’ DNA were then added to a standard PCR
mixture containing 0.75 mmolrl MgCl and the specific 2
primers flanking the CCGG site in the promoter region of
the gene. PCR amplification was performed for 35 cycles
denaturation: 938C 30 s; annealing 588C 30 s; extension
. 728C 1 min; final extension 728C 10 min . The PCR
products were resolved by electrophoresis through a 1.8%
agarose gel and visualised using ethidium bromide stain-
ing.
Under the conditions described above, no amplification
band should be seen after digesting the genomic DNA with
MspI; this acts as a negative control. However, the ex-
treme sensitivity of the PCR means that on occasions low
residual levels of undigested DNA are detectable. If the
site is completely unmethylated, the DNA should be
cleaved by HpaII, and no band will be seen after PCR
amplification. The target sequence will be amplified nor-
. mally i if the site is completely methylated or hemi-meth-
. ylated and no digestion occurs with HpaII, and ii when
the genomic DNA is incubated with restriction enzyme
buffer only.
2.5. Analysis of methylation patterns using the bisulphite-
PCR method
This method relies on the ability of bisulphite to convert
efficiently a cytosine residue to uracil in single-stranded
DNA, whilst leaving 5-methylcytosine residues unaltered
wx 10,11 . The conversion of cytosine to uracil produces 2
 non-complementary modified DNA strands uracils cannot
. pair with guanines on the opposite strand which can then
be amplified separately by PCR with primer pairs specific
 for each converted strand during PCR a uracil base is read
as thymine by the DNA polymerase, while 5-methylcyto-
. sine, which remains unchanged, is read as cytosine .
Fig. 1. Analysis of the extent of methylation at a CCGG site using the restriction enzymes MspI and HpaII. After digestion with the restriction enzymes
. MspI and HpaII,a;450 bp segment spanning a CCGG site bases 2462 to 2465 in the promoter region of the b-MHC gene was amplified using
. myocardial and leucocyte DNA from 3 individuals. No amplification is observed with genomic DNA samples after digestion with MspI M, a
. methylation-insensitive restriction. A PCR band was observed in the HpaII H -digested samples from leucocytes, but not atrial myocardium. An
. amplification band is observed in all the samples pre-treated with restriction enzyme buffer alone B ; this acts as a positive control. The very faint PCR
. products observed in the leucocyte M lanes of patients 2 and 3 are due to small amounts of residual undigested genomic DNA which have been amplified
by the very sensitive PCR technique. Lsmolecular weight ladder.
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. Twenty-four ml of genomic DNA 250 mgrml was
digested for 1 h at 378C with 3 ml of the restriction
enzyme BamHI and 3 mlo f1 0 = restriction enzyme
buffer in a final volume of 30 ml. 6 ml of 1.8 M NaOH
 was added final concentration 0.3 M in a final volume of
. 36 ml and incubated at 378C for 15 min to denature the
 DNA. 4 ml 10 mmolrl hydroquinone final concentration
. 0.5 mmolrl and 40 ml 4 M sodium bisulphite pH 5 final
. . concentration 2 M were added final volume of 80 ml.
 All solutions were freshly prepared with minimal shaking
. of the sodium bisulphite solution . The sample was then
covered with oil and incubated for 6 cycles of temperature
cycling at 558C for 3 h and 958C for 3 min. Our unpub-
lished preliminary results showed that this protocol en-
sured complete conversion of cytosine bases to uracil by
bisulphite, whilst methylcytosines remained unchanged.
The DNA was purified using the Wizard DNA Clean-Up
. system according to manufacturer’s instructions Promega ,
. and eluted in 50 ml of Tris HCl 50 mmolrl, pH 8.0
. rEDTA 1 mmolrl buffer. 10 ml of 1.8 M NaOH were
added, and the reagents were incubated at 378C for 15 min
to ensure complete desulphonation. The solution was neu-
tralised by adding 40 ml 7.5 M ammonium acetate pH 7,
and the DNA was then precipitated with 100 ml of iso-
propanol. After the DNA was pelleted by centrifuging at
14000 g for 15 min, the supernatant was removed and the
pellet was resuspended in 10 ml of distilled water. This
bisulphite-converted DNA was amplified for 40 cycles by
 PCR denaturation: 938C 30 s; annealing 558C 30 s; exten-
. sion 728C 1 min; final extension 728C 10 min using a
standard reaction mix containing 1 U Prozyme and 2
mmolrl MgCl . Primers were designed to recognise only 2
the bisulphite-converted DNA according to the protocol of
wx 
X Frommer et al. 10 forward: 5-AGTAGTGTTTAGGGT-
TAGAAGTGTTGTG; reverse: 5
X-ATCTCAAAAAC-
. TATATATATAAAACAAC . Finally, the amplified DNA
was sequenced using the AmpliTaq FS automated cycle-
. sequencing kit Perkin-Elmer as recommended by the
supplier. The fluorescent dideoxy terminated products were
resolved on an ABI 373 automated sequencer.
2.5.1. Declaration
The investigation conforms with the principles outlined
 in the Declaration of Helsinki Cardiovascular Research
. 1997;35:2–3 .
3. Results
3.1. Methylation patterns in lymphocytes and myocytes
Amplification of genomic DNA after digestion with the
restriction enzymes MspI and HpaII permits assessment
of the degree of methylation of specific CCGG restriction
sites. Fig. 1 shows the results of amplifying a ;450 bp
. segment spanning a CCGG site bases 2462 to 2465 in the
promoter region of the b-MHC gene using myocardial and
leucocyte DNA. In DNA samples pre-digested with MspI,
an enzyme which cleaves the CCGG site irrespective of
the level of methylation of the CG dinucleotide, very little,
or no, DNA amplification is observed. Where weak bands
. are observed e.g. patients 2 and 3 , this is likely to
represent amplification of very small amounts of undi-
gested DNA. On the other hand, a bright amplification
band is observed in the HpaII-digested samples from
leucocytes, but not atrial myocardium, indicating that the
CG dinucleotide is methylated in leucocyte, but not my-
ocardial genomic DNA. An amplification band is observed
in all the samples pre-treated with restriction enzyme
buffer alone; this acts as a positive control.
 Bisulphite converts unmethylated cytosine to uracil de-
. tected as thymine after PCR , whereas methylated cytosine
Fig. 2. Bisulphite-PCR analysis of methylation of the promoter region of
the b-MHC gene. Unmethylated cytosines occurring outside CG dinu-
 cleotides are converted by bisulphite to uracil which is detected as
. thymine after PCR , whereas methylcytosines remain unchanged. Typical
electropherograms from the ABI 373 automated sequencer are shown in
the region of the CG dinucleotides in the 3 regulatory elements of the
b-MHC gene that contain these dinucleotides. In the leucocyte samples,
the CG dinucleotides remain largely unchanged after bisulphite treatment.
However, in the atrial samples from the same patient there is greater
CªT conversion in CG dinucleotides, indicating that the degree of
methylation of CG dinucleotides is relatively low.
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remains unchanged. At the CCGG site in the b-MHC
promoter, the results were consistent with those obtained
by restriction analysis with HpaII and MspI and indicated
that there was almost complete demethylation of the CG
dinucleotide in atrial tissue, the reverse being the case in
. leucocytes data not shown . Fig. 2 shows the electro-
pherograms of samples from the same individual in the
region of the CG dinucleotides in the 3 regulatory ele-
ments of the b-MHC gene that contain these dinucleotides
. Table 1 . In the leucocyte samples, the CG dinucleotides
 remain largely unchanged after bisulphite treatment i.e. C
. peak))T peak . On the other hand, in the atrial samples
we have found that there is variable C ª T conversion in
the regulatory elements, but with a significant T peak
present in all cases, indicating that many of the CG
dinucleotides are unmethylated. When the degree of meth-
ylation was compared between individuals, we observed
consistent methylation in leucocyte DNA in the 3 elements
similar to that shown in Fig. 2. However, in atrial DNA
samples the level of methylation in each of the elements
 varied between individuals Fig. 3 shows the results for
. one of the elements in 3 different individuals .
3.2. Expression of the b-MHC gene in leucocytes and
atrial myocytes
To assay the steady-state prevalence of b-MHC mRNA
we used RT-PCR to amplify b-MHC cDNA. After se-
quencing PCR products from atrial samples with fluores-
cent dideoxy terminators, we compared the sequence of the
amplification bands in the region of exon 11 of b-MHC
and a-MHC, where there are significant differences in
nucleotide sequence. We established conclusively that the
single ;550 bp product obtained after PCR of atrial
samples was derived solely from the b-MHC cDNA,
Fig. 3. Inter-individual variation of methylation of the b-MHC promoter
in atrial DNA. Typical sequencing electropherograms obtained from
bisulphite-PCR products in the region of the CG dinucleotide in one of
 the regulatory elements of the human b-MHC gene TTGGTGGTCGTG-
. GTCAGT . The variability of the relative C and T peak heights suggests
that there is variation in the degree of methylation of the CG dinucleotide
in this regulatory element.
Fig. 4. Expression of the b-MHC gene in leucocytes and atrial myocytes.
The steady-state prevalence of b-MHC mRNA was assessed using re-
verse transcription-PCR to amplify b-MHC cDNA. After electrophoretic
separation of the PCR products a single major DNA band was seen in the
atrial sample lanes. DNA sequencing established that it was derived from
b-MHC cDNA. After a single round of amplification, b-MHC cDNA
. band was readily detectable in the atrial myocardial samples H1 and H2 ,
. but not in leucocyte cDNA samples L1 and L2 , indicating that the
steady-state prevalence of b-MHC mRNA transcripts in the latter was
below the level of detection by this PCR method. The faint bands in the 2
leucocyte lanes are non-specific amplification products that arise in the
absence of specific b-MHC cDNA amplification. M is the molecular
weight ladder.
 without contamination with a-MHC cDNA data not
. shown .
As shown in Fig. 4, b-MHC cDNA was readily de-
tectable after a single round of amplification in all atrial
myocardial samples, but not in leucocyte cDNA samples,
indicating that the steady-state prevalence of b-MHC tran-
scripts in the latter was below the level of detection by this
PCR method. The faint bands observed in the leucocyte
lanes are non-specific amplification products that com-
monly arise in the absence of specific products.
4. Discussion
Here we present evidence which indicates that methyla-
tion of regulatory elements within the 5
X region of the
b-MHC gene is inversely related to mRNA steady-state
levels. Functional assays of b-MHC promoterrreporter
plasmids containing progressive deletions of the 5
X region
of the gene have revealed that there are strong positive and
negative elements between positions y340 and y200
wx upstream from the transcription start site 3 ; some of these
contain CG dinucleotides that are susceptible to methyla-
tion. We provide evidence that in atrial myocytes these
sites are predominantly hypo-methylated and the gene is
strongly expressed. In leucocytes, where ‘illegitimate’ gene
transcription has only been observed by nested reverse
wx transcription-PCR 12 , and the protein is undetectable, the
promoter elements are heavily methylated. Methylation is
known to silence genes, and it is likely that these differ-
ences in expression are due to reduced transcription, rather
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than increased degradation. Furthermore, it is unlikely that
a-MHC cDNA contributed significantly to the results
shown in Fig. 4. To validate the reverse transcription-PCR
data, we sequenced the ;550 bp amplification band
obtained from the atrial samples. Although the sequences
of a-MHC and b-MHC mRNAs are remarkably similar,
there are significant base changes in the region of exon 11.
These differences were sufficient to confirm that a-MHC
cDNA was not detectable in the specific PCR bands
observed in the atrial samples shown in Fig. 4, and demon-
strate that the PCR primers used were specific for b-MHC
cDNA under our amplification conditions.
After bisulphite conversion, we have observed some
variability in the relative C and T peak heights of the
electropherograms from different individuals at CG dinu-
cleotides within the regulatory elements in atrial DNA
. samples e.g. Fig. 3 . There are 3 possible explanations for
these observations. First, it may simply reflect technical
artefact due to variability in the efficacy of bisulphite to
convert unmethylated cytosines. We do not favour this
possibility because we have found that all cytosines that do
not occur in CG dinucleotides are consistently converted
by this reagent in our protocol. Secondly, the difference
may result from complete methylation of a site in some
cells and complete demethylation in other myocytes, with
the proportions of each type varying between individuals.
This may be the case, at least to some extent, given that in
atrial tissue there is marked cellular heterogeneity in the
expression of each MHC; cells containing only a-MHC
presumably with heavy methylation of the b-MHC gene
. and complete repression of expression can be found adja-
 cent to cells expressing only b-MHC containing hypo-
. methylated b-MHC promoters , whilst others contain both
wx MHCs 13,14 . Finally, it may be due to variable methyla-
tion of one or other allele within a single cell. All the
myocardial samples analysed in these studies consisted of
many thousands of myocytes, and it is not possible to
distinguish between the latter two alternatives. We are in
the process of refining techniques to assess differential
expression of b-MHC alleles using single-cell PCR. How-
ever, at present it is not possible to quantify accurately the
level of methylation in single-cell preparations.
There are several lines of evidence implicating methyla-
tion of critical regulatory regions in the control of expres-
sion of a number of genes. For instance, there is an inverse
relationship between expression of the murine MyoD gene
wx 15 and the avian myosin light chain MLC1f and MLC3f
wx genes 16 , and the level of methylation of promoter
elements. Similar results have been obtained for a variety
wx of non-myocyte genes 17–20 . Alteration of the methyla-
tion status of regulatory elements of various genes by in
wx vitro methylation analysis 17–25 and by administration
of the demethylating agents 5-aza-2
X-deoxycytidine, 5-
wx azacytidine or 3-deazaadenosine 5,26–29 has been shown
to have a profound effect on their expression. In addition,
methylation of cytosine residues is thought to play a major
role in producing hemizygous expression of imprinted and
X-linked genes by permanently altering chromatin struc-
ture or by promoting attachment of methylcytosine binding
wx proteins 30–32 .
Our results therefore raise a number of interesting ques-
tions. First, the inverse relationship between the level of
expression of the b-MHC gene and the degree of methyla-
tion of regulatory elements suggests that the latter may be
involved in the dramatic changes in cardiac myosin iso-
forms observed during ontogeny, eventually leading to the
establishment of the tissue specific pattern of expression of
this gene in the adult. In rats and rabbits, b-MHC is more
abundant than a-MHC in the late foetal ventricle. How-
ever, soon after birth the isomyosin profile begins to
change to the a-MHC form. The rat ventricle then main-
tains the predominance of a-MHC, whilst the rabbit re-
verts back towards the b-MHC form. On the other hand, in
the human ventricle b-MHC predominates at all stages of
development, a-MHC constituting no more than 15% of
wx the total myosin in the adult healthy left ventricle 33 . In
human atria, a-MHC predominates, but b-MHC is present
in substantial amounts and can be up-regulated further by
. pressure overload see below .
Secondly, we speculate that during the process of car-
diac myocyte hypertrophy changes in genomic DNA meth-
ylation may play a role in co-ordinating the programme of
wx gene expression 1,4 . Although a myosin isoform shift is
not observed in the adult human ventricle in response to
hypertrophic stimuli, atrial b-MHC expression increases
further in proportion to the extent of atrial distension
wx associated with valvular disease 14,34 . When the rodent
ventricles hypertrophy there is a ‘recapitulation’ of the
foetal pattern of MHC gene expression which results in
up-regulation of b-MHC gene and down-regulation of
a-MHC expression, with replacement of a-MHC by b-
wx MHC in the thick filaments 1 . We propose that in cardiac
tissues these changes are accompanied by reciprocal alter-
ation of promoter methylation, whilst in tissues that do not
express b-MHC, such as peripheral blood leucocytes, the
almost complete methylation of regulatory elements re-
mains relatively fixed.
Finally, we raise the exciting possibility that ‘new’
cardiac myocytes could be generated by altering the phe-
notype of non-myocyte ventricular cells such as fibroblasts
with agents which demethylate genomic DNA. There are
already striking precedents for this. When undifferentiated
mouse fibroblasts were treated for 24 h with 5-azacytidine,
a cytosine analogue that inhibits DNA methyl-transferases
and produces genomic demethylation, a small proportion
of the cells differentiated into multinucleate striated mus-
wx
X cle cells that twitched 35 . A similar chemical, 5-aza-2 -
deoxycytidine, has also been shown to enhance the effi-
cacy of the myogenic determination factor, MyoD,t o
wx induce expression of myosin in fibroblasts 36,37 . We are
now evaluating the efficacy of demethylating agents to
change their phenotype of human cardiac fibroblasts into
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contractile myocytes. These studies are important in the
context of myocardial diseases characterised by ventricular
myocardial insufficiency, such as myocardial infarction
and hypoplastic ventricle syndromes, where the restoration
of ventricular function would have a major impact on
prognosis.
In conclusion, we have demonstrated an inverse rela-
tionship between the level of expression of the b-MHC
gene and the degree of methylation of 5
X regulatory ele-
ments. We propose that methylation of promoter motifs
plays a role in the processes determining tissue-specific
expression, and perhaps also in the coordinated programme
of gene expression that characterises cardiac myocyte hy-
pertrophy.
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